A Phase 3 Open-Label, Randomized, Multicenter Study of Rocbrutinib (LP-168) vs Pirtobrutinib in Covalent BTK Inhibitor (cBTKi) Pretreated Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Lymphoma (SLL) Subjects
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 入组人数
- 306
- 试验地点
- 6
- 主要终点
- PFS assessed by IRC
研究概览
简要总结
This is a Phase 3, randomized, open-label, multicenter study comparing rocbrutinib (LP-168) versus pirtobrutinib in adult participants with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have previously received a covalent Bruton's tyrosine kinase inhibitor (cBTKi). Approximately 306 participants will be randomized 1:1 to receive rocbrutinib 200 mg orally once daily or pirtobrutinib 200 mg orally once daily, administered continuously in 28-day cycles until disease progression, unacceptable toxicity, withdrawal of consent, or other discontinuation criteria are met. Randomization will be stratified by presence of del(17p)/TP53 mutation (yes/no), reason for discontinuation of prior cBTKi therapy (toxicity vs disease progression), prior exposure to a BCL2 inhibitor (yes/no), and region (United States/China/rest of world). The primary endpoint is progression-free survival (PFS) assessed by an independent review committee (IRC) using iwCLL 2018 criteria for CLL and Lugano 2014 criteria for SLL. Key secondary objectives include overall survival, overall response rate, time-to-event outcomes, and safety/tolerability; exploratory objectives include health-related quality of life and biomarker assessments.
详细描述
Chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) are indolent B-cell malignancies characterized by accumulation of mature but dysfunctional lymphocytes. Covalent Bruton's tyrosine kinase inhibitors (cBTKis) have substantially improved outcomes for patients with CLL/SLL; however, disease progression on cBTKi therapy or intolerance leading to treatment discontinuation remains an important clinical challenge. Patients who discontinue cBTKi therapy due to progression have limited therapeutic options and may experience poor outcomes. Therefore, effective and well-tolerated therapies are needed for participants with relapsed or refractory (R/R) CLL/SLL who have previously received a covalent BTK inhibitor.
Rocbrutinib (LP-168) is a selective next-generation inhibitor of BTK, that can irreversibly inhibit WT BTK, and reversibly inhibit C481 mutated BTK, with activity against known resistance mutations for non-covalent BTKi, under investigation for the treatment of CLL/SLL. Pirtobrutinib is an oral BTK inhibitor with regulatory approval for adults with R/R CLL/SLL who have previously received a covalent BTK inhibitor (cBTKi). This Phase 3 study is designed to compare the efficacy and safety of rocbrutinib versus pirtobrutinib in adult participants with cBTKi-pretreated R/R CLL/SLL.
This is a Phase 3, randomized, open-label, multicenter study conducted at approximately 100 sites globally. Approximately 306 participants will be randomized in a 1:1 ratio to receive rocbrutinib (LP-168) or pirtobrutinib. Eligible participants are adults with confirmed R/R CLL or SLL who require therapy and have received prior treatment with a cBTKi. Participants may have received additional prior systemic therapies, including prior exposure to a BCL2 inhibitor. Key exclusion criteria include central nervous system involvement by CLL/SLL and clinically significant cardiovascular conditions, including uncontrolled arrhythmias and clinically relevant QTc prolongation.
Participants randomized to the investigational arm will receive rocbrutinib 200 mg orally once daily. Participants randomized to the active comparator arm will receive pirtobrutinib 200 mg orally once daily. Study treatments will be administered continuously in 28-day cycles until disease progression, unacceptable toxicity, withdrawal of consent, or other protocol-defined discontinuation criteria. Crossover between treatment arms is not permitted.
Randomization will be stratified based on prognostic and treatment-history factors, including: (1) del(17p) and/or TP53 mutation status, (2) reason for discontinuation of prior cBTKi therapy, (3) prior exposure to a BCL2 inhibitor, and (4) geographic region.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age ≥18 years;
- •Histologically confirmed CLL/SLL iwCLL 2018;
- •Relapsed or refractory disease requiring treatment;
- •Previously treated with prior lines of therapy including a covalent BTK inhibitor;
- •Measurable disease;
- •ECOG 0-2;
- •Adequate marrow, hepatic, and renal function;
- •TP53 mutation status confirmed by NGS;
- •17p deletion status confirmed by FISH;
排除标准
- •Prior ncBTKi or BTK degraders;
- •Richter's transformation;
- •Confirmed prolymphocytic leukemia;
- •Uncontrolled comorbidities or infections;
- •Known CNS involvement by CLL/SLL;
- •Prior malignancy requiring active treatment (except certain adequately treated cancers) per protocol;
- •Pregnancy or breastfeeding;
- •Concomitant medications or conditions prohibited by protocol (e.g., strong drug-drug interaction risk);
研究组 & 干预措施
Pirtobrutinib
200mg daily
干预措施: Pirtobrutinib (Drug)
Rocbrutinib
200mg daily
干预措施: Rocbrutinib (Drug)
结局指标
主要结局
PFS assessed by IRC
时间窗: From randomization until disease progression or death from any cause, assessed up to approximately 4 years.
Progression-Free Survival assessed by independent review committee. PFS is defined as the time from the date of randomization to disease progression or death from any cause, whichever occurs first. Those who do not experience disease progression or death at the time of analysis are censored according to the last evaluation time point.
次要结局
- OS(From randomization until death from any cause, assessed up to approximately 4 years)
- PFS assessed by INV(From randomization until disease progression or death from any cause, assessed up to approximately 4 years.)
- ORR(From randomization until disease progression, assessed up to approximately 4 years)
- DOR(From first documented response until disease progression or death, assessed up to approximately 4 years)
- TTNT(From randomization to start of next anti-CLL/SLL treatment, assessed up to approximately 4 years.)
- EFS(From randomization until an event occurs, assessed up to approximately 4 years.)
- Safety and tolerability(From first dose through 30 days after the last dose of study treatment (up to approximately 4 years))